ArticleCureus2025
Outcomes of Fixed-Dose Radioactive Iodine Therapy in Hyperthyroidism and Optimization of Follow-Up After Treatment Failure With Low-Dose Antithyroid Medication.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preliminary volume-based optimization of radioactive iodine dose without radioactive iodine uptake in Graves' disease.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFixed-dose radioactive iodine (RAI) therapy is a common treatment for hyperthyroidism. However, the optimal follow-up duration and management strategies for patients experiencing treatment failure remain uncertain. This study evaluates the outcomes of fixed-dose RAI therapy in hyperthyroid patients and explores the appropriate follow-up duration for those requiring low-dose antithyroid drugs (ATDs) after initial treatment failure.
methodsA retrospective cohort study was conducted, including 204 hyperthyroid patients who received their first fixed-dose RAI treatment at Ratchaburi Hospital, Na Muang, Ratchaburi, Thailand, between December 2022 and May 2024. Treatment outcomes were assessed six months post RAI. Among the 98 patients with treatment failure, those who remained euthyroid on low-dose ATDs were followed for up to nine months to evaluate long-term outcomes. The study analyzed remission rates, progression to hypothyroidism, and the need for additional RAI therapy using descriptive statistics and Kaplan-Meier survival analysis.
resultsOf the 204 patients, 106 (52%) achieved remission within six months post RAI. Among the 201 patients with Graves' disease, 104 (51.7%) achieved remission. Of the 98 patients with treatment failure, 40 remained euthyroid on low-dose ATDs. After nine months of extended follow-up, nine (37.5%) maintained euthyroid status, four (16.7%) developed hypothyroidism, and 11 (45.8%) required a second RAI treatment. The median time to treatment failure was 6.9 months, suggesting that some patients may stabilize without immediate re-treatment.
conclusionRAI therapy is effective for hyperthyroidism. Extended follow-up without rushing to a second RAI dose may be sufficient for patients who remain euthyroid on low-dose ATDs, helping reduce unnecessary radiation exposure. However, further prospective studies are needed to establish guidelines for optimal follow-up and re-treatment timing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.